In light of data shared, HMTM has prospective broad applicability for a wide demographic contributing to equity of access to new treatment options.
TauRx has initiated regulatory engagement in the UK and the US for intended product approval. Other territories will follow in line with plans to scale commercialisation of HMTM.
For additional information, please visit: https://taurx.com/ or https://adpd.kenes.com/. ;